Findings from the EMERALD-1 and EMERALD-3 studies suggest that further evidence of benefit is needed and to reflect on the use of surrogate endpoints

While the IMbrave152/SKYSCRAPER-14 trial showed no added benefit with tiragolumab, other studies are ongoing to explore the potential of additional immune checkpoint inhibition in combination with standard therapy

Potentially practice-changing data were presented for atezolizumab plus bevacizumab, and camrelizumab plus rivoceranib in hepatocellular carcinoma

Study indicates that PARP inhibition could extend treatment options for patients with biliary tract cancers

Data from the TALENTACE trial add to growing evidence supporting the combination of immunotherapy plus anti-VEGF component with TACE

Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion

Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function

Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients

Positive data presented from the LEAP-012 study for intermediate-stage disease, but it is still unclear how these will influence clinical practice